Matthias von Herrath

Company: Novo Nordisk

Job title: Vice President & Senior Medical Officer, Global Chief Medical Officer

Seminars:

The Struggles with Immune Biomarkers and Pathologic Endotypes in Type 1 Diabetes 2:00 pm

Immune biomarkers exhibit substantial longitudinal variation in humans, they have so far failed to predict individual trajectories Pathologically in the human pancreas there is little evidence for completely different endotypes/pathways comparing individuals We have, to date, no reliable marker for antigenic tolerance that correlate reliably with clinical endpoints – learning across diseases will be neededRead more

day: Day One